Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell of proximal tubule | 7 studies | 35% ± 12% | |
kidney loop of Henle epithelial cell | 6 studies | 31% ± 6% | |
hepatocyte | 5 studies | 40% ± 22% | |
abnormal cell | 4 studies | 24% ± 2% | |
epithelial cell | 4 studies | 48% ± 13% | |
pancreatic A cell | 3 studies | 32% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 6930.95 | 226 / 226 | 99% | 107.13 | 400 / 406 |
kidney | 100% | 8843.57 | 89 / 89 | 98% | 152.14 | 884 / 901 |
thymus | 100% | 2294.83 | 653 / 653 | 98% | 43.82 | 593 / 605 |
pancreas | 100% | 3299.51 | 328 / 328 | 95% | 47.22 | 169 / 178 |
breast | 100% | 1605.92 | 459 / 459 | 95% | 33.92 | 1058 / 1118 |
prostate | 100% | 2256.16 | 245 / 245 | 94% | 24.41 | 470 / 502 |
ovary | 100% | 1870.38 | 180 / 180 | 91% | 23.46 | 392 / 430 |
stomach | 100% | 1881.12 | 359 / 359 | 91% | 27.80 | 260 / 286 |
lung | 99% | 1541.56 | 571 / 578 | 92% | 33.66 | 1062 / 1155 |
uterus | 100% | 2799.52 | 170 / 170 | 90% | 28.42 | 413 / 459 |
intestine | 100% | 1731.32 | 966 / 966 | 88% | 27.73 | 465 / 527 |
bladder | 100% | 2748.52 | 21 / 21 | 86% | 27.42 | 432 / 504 |
skin | 99% | 1562.90 | 1790 / 1809 | 86% | 24.21 | 407 / 472 |
esophagus | 100% | 1925.64 | 1445 / 1445 | 84% | 22.86 | 154 / 183 |
adrenal gland | 100% | 2663.00 | 258 / 258 | 82% | 22.35 | 189 / 230 |
brain | 86% | 809.62 | 2280 / 2642 | 81% | 22.62 | 573 / 705 |
spleen | 100% | 1177.83 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2134.00 | 1331 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 1433.41 | 1197 / 1204 | 0% | 0 | 0 / 0 |
heart | 94% | 1507.33 | 808 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 35.88 | 27 / 29 |
muscle | 84% | 657.75 | 676 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 73% | 19.01 | 33 / 45 |
eye | 0% | 0 | 0 / 0 | 48% | 9.66 | 38 / 80 |
peripheral blood | 29% | 1777.96 | 273 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007601 | Biological process | visual perception |
GO_0042178 | Biological process | xenobiotic catabolic process |
GO_0051289 | Biological process | protein homotetramerization |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0003960 | Molecular function | NADPH:quinone reductase activity |
GO_0070402 | Molecular function | NADPH binding |
GO_0003730 | Molecular function | mRNA 3'-UTR binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0070404 | Molecular function | NADH binding |
Gene name | CRYZ |
Protein name | Quinone oxidoreductase (EC 1.6.5.5) (NADPH:quinone reductase) (Zeta-crystallin) |
Synonyms | |
Description | FUNCTION: Does not have alcohol dehydrogenase activity. Binds NADP and acts through a one-electron transfer process. Orthoquinones, such as 1,2-naphthoquinone or 9,10-phenanthrenequinone, are the best substrates (in vitro). May act in the detoxification of xenobiotics. Interacts with (AU)-rich elements (ARE) in the 3'-UTR of target mRNA species. Enhances the stability of mRNA coding for BCL2. NADPH binding interferes with mRNA binding. . |
Accessions | Q08257 ENST00000370870.5 C9JH92 ENST00000340866.10 [Q08257-1] ENST00000441120.1 ENST00000370872.7 [Q08257-2] ENST00000370871.7 [Q08257-3] ENST00000417775.5 [Q08257-1] A6NP24 |